Fig. 2

The Kaplan–Meier curves of DFS and OS for ER+/PR + and ER+/PR- breast cancer patients with and without adjuvant ET. Adjuvant ET is associated with better DFS (A) and OS (C) in ER+/PR + patients. Adjuvant ET cannot improve DFS (B) and OS (D) in ER+/PR- patients. DFS, disease-free survival; OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; ET, endocrine treatment.